Visit to England: What Did We Learn?
We just returned from a brief trip to England, where we met with a client, plus a few friends and colleagues. Over several meetings and meals, three issues consistently came…
We just returned from a brief trip to England, where we met with a client, plus a few friends and colleagues. Over several meetings and meals, three issues consistently came…
Last week, the US Centers for Disease Control published a rather alarming report on drug overdose deaths in the US. Here are a few items which we found…
BIO starts in June, right? Wrong. Perhaps BIO starts in late April, when partnering opens? Sorry. Wrong again. BIO started the moment you decided to…
We recently learned about Bayer's Grants4Apps program. This program provides support to companies and projects involving "...novel software, hardware, technologies...contributing to improve health outcomes or pharmaceutical processes." Bayer is…
This is a good question...a question which lacks a simple answer without quite a bit of analysis. We audit out-licensing processes, and there are times when the answer is…
Yeah, it rained last week in San Francisco. But the rain did not stop untold thousands of us from gathering at the many hotels, watering holes, and coffee shops around…
I believe it is fair to say that 2016 was a bit unusual. Thinking about the terminology many of us learned last year leads us to that conclusion: snowflake,…
The recent elections in the United States is bringing many long-standing policies into question. And, the continued legalization of marijuana is one of them. At Lacerta Bio, we have consistently…
Few of us will soon forget waking up in Cologne to the news that we will soon have a "President Trump" in the Oval Office in a few months. So,…
BIO Europe was, yet again, an excellent conference for Lacerta Bio. Having the US election on television screens in the Exhibition Hall made for some surreal moments and discussions. Not a…